期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血管紧张素受体拮抗剂在心房颤动中的作用:启示与困惑

原文传递
导出
摘要 心房颤动是最常见的心律失常，人群患病率约为0．4％～1．0％。随着社会人口老龄化的到来，心房颤动的患病率也随之增加，心房颤动导致脑卒中、心力衰竭和死亡的增加，对公共健康构成了较大的威胁。近年来，尽管对心房颤动的药物治疗和微创手术有了深入了解，但窦性心律的维持却不尽人意。因此，人们一直在探讨预防和治疗心房颤动更有效的药物。
作者 冯颖青
机构地区 广东省人民医院
出处 《中华高血压杂志》 CAS CSCD 北大核心 2012年第11期1013-1016,共4页 Chinese Journal of Hypertension
关键词 血管紧张素受体拮抗剂 心房颤动 药物治疗 人口老龄化 心律失常 心力衰竭 公共健康 微创手术
分类号 R541.75 [医药卫生—心血管疾病]
  • 相关文献

参考文献32

  • 1Zhou Z, Hu D. An epidemiological study on the prevalence of at- rial fibrillation in the Chinese population of China's Mainland[J]. J Epidemiol,2008,18(5) :209-216.
  • 2Stefansdottir H, Aspelund T, Gudnason V, et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future proj ections[J]. Europace, 2011,13 (8) : 1110-1117.
  • 3Disertori M, Latini R, Maggioni AP, et al. On behalf of the GIS SI-AF investigators. Rationale and design of the GISSI-atrial fi- brillation trial: randomized, prospective, multicentre study on the use of valsartan, an angiotensin Ⅱ AT1-receptor blocker, in the prevention of atrial fibrillation recurrence[J]. J Cardiovasc Med, 2006,7(1) :29-38.
  • 4Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation~ 20-year fol- low-up of the Renfrew/Paisley study[J]. Am J Med, 2002,113 (5) :359-364.
  • 5Chiang CE, Naditch-Brfilfi L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibril- lation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international reg- istry[J]. Cite Arrhythm Eleetrophysiol,2012,5(4) :632-639.
  • 6Nakashima H, Kumagai K, Umta H, et al. Angiotensin Ⅱ an- tagonist prevents electrical remodelling in atrial fibrillation[J]. Circulation, 2000,101(22) :2612-2617.
  • 7Quignard JF, Mironneau J, Carricaburu V, et al. Phosphoinosit- ide 3-kinase gamma mediates angiotensin Ⅱ-induced stimulation of L-type calcium channels in vascular myocytes[J]. J Biol Chem, 2001,276(35) :32545 -32551.
  • 8Berk BC. Angiotensin Ⅱ signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases[J]. J Am Soc Nephrol, 1999,10(Suppl 11) :S62-68.
  • 9Kaibara M, Mitarai S, Yano K, et al. Involvement of Na^+-H^+ antiporter in regulation of Ltype Ca2+ channel current by angio- tensin Ⅱ in rabbit ventricular myocytes[J]. Circ Res, 1994, 75 (6) : 1121-1125.
  • 10Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-conver- ting enzyme inhibition on the development of atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure[J]. Circulation, 2001,104(21) : 2608-2614.

二级参考文献11

  • 1杨俊,黄从新,江洪,王腾.厄贝沙坦电生理作用的实验研究[J].第四军医大学学报,2005,26(1):17-21. 被引量：6
  • 2殷跃辉,刘增长,吴近近,代引,苏立,兰先彬,凌智瑜,杨小渝,罗开良.胺碘酮与氯沙坦、培哚普利联合治疗阵发性心房颤动的前瞻、随机开放研究[J].中华心血管病杂志,2006,34(4):299-302. 被引量：72
  • 3Pedersen 0 D, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction [ J ]. Circulation, 1999 , 100 ( 4 ) : 376-380.
  • 4Shinagawa K, Derakhchan K, Nattel S. Pharmacological prevention of atrial tachycardia induced atrial remodeling as a potential therapeutic strategy [ J ] . Pacing Clin Electrophysiol, 2003,26(3) :752-764.
  • 5AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation:an AFFIRM substudy of the first antiarrhythmic drug [J] . J Am Coll Cardiol, 2003,42( 1 ) :20-29.
  • 6Goette A, Amdt M, Rocken C, et al. Regulation of angiotensin Ⅱ receptor subtypes during atrial fibrillation in humans [J]. Circulation, 2000,101 (23) :2678-2681.
  • 7Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin Ⅱ Type Ⅰ receptor antagonist on electrical and structural remodeling in atrial fibrillation [ J ] . J Am Coll Cardiol, 2003,41(12) :2197-2204.
  • 8Hideko N, Koickiro K, Hidenori U, et al. Angiotensin Ⅱ antagonist prevents electrical remodeling in atrial fibrillation [J]. Circulation, 2000,101(22) :2612-2617.
  • 9Marcello D, Roberto L, Aldo P M, et al. Rationale and design of the GISSI-atrial fibrillation trial: a randomized, prospective, muhicentre study on the use of valsartan, an angiotensin Ⅱ ATI-receptorblocker, in the prevention of atrial fibrillation recurrence [ J ] . Ital Feder Cardiol, 2006 , 7 ( 4 ) : 29-38.
  • 10Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin Ⅱ type Ⅰ receptor antagonist on electrical and structural remodeling in atrial fibrillation [ J ]. J Am Coll Cardiol,2003,41(12) :2197-2204

共引文献11

中华高血压杂志
2012年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部